论文部分内容阅读
本文作者检测了23例急粒、粒-单、急单及5例缓解一年以上的急性白血病患者尿中芳香基硫酸酯酶(简称AS)活性,剔除了尿中肌酐增高及尿常规异常的标本。并对24小时尿与一次晨尿标本的测定结果做了对比。同时测定尿中碱性磷酸酶(AKP)、与乳酸脱氢酶(LDH),按照骨髓指数(BMI)=[(%细胞增生度/100)+1)×[(%原始细胞/100)+1]的算式。计算BMI以代表骨髓病情(正常值1.3～1.6,可能范围1～4)。结果表明尿中AKP与LDH无一致性变化,AKP与LDH在疾病进行时增高者仅分别为30.4%、43.5%,而尿中AS-人与AS-B活性增高者分别为100%、95.7%,缓解时恢复正常。1例缓解一年半的患者在骨髓发现复发前4个月AS已升高。22例患者作了骨穿与A S的系列测定,表明BMI增高时酶活性也增高,缓解时BMI降低酶活性也下降。
In this study, we detected the activity of aryl sulfatase (AS) in urine of 23 patients with acute pellet, granulo-single and acute one, and 5 patients with acute leukemia that were relieved for more than one year. The urinary creatinine excretion and urinary abnormalities specimen. And 24 hours urine and morning urine samples were compared results. Urinary alkaline phosphatase (AKP) and lactate dehydrogenase (LDH) were measured simultaneously according to the bone marrow index (BMI) = [(% cell proliferation / 100) 1]. The BMI is calculated to represent the condition of the bone marrow (normal 1.3 to 1.6, possible range 1 to 4). The results showed that urinary AKP and LDH did not change in consistency, AKP and LDH elevated disease were only 30.4%, 43.5%, while urinary AS- and AS-B activity were increased were 100%, 95.7% , Ease when returned to normal. One patient who had been relieved for one and a year and a half years had AS elevated 4 months before the bone marrow was found to have relapsed. Twenty-two patients underwent a series of measurements of bone penetration and A S, indicating that the enzyme activity was also increased when the BMI was increased, and the enzyme activity was also decreased when the BMI was relieved.